Sigachi Sets Up $1 Million R&D Hub in Hyderabad to Power Global Pharma Push

Image Source: GoodReturns

Sigachi Industries Ltd, a leading name in pharmaceutical excipients and APIs, has announced a $1 million investment to establish a new research and development centre in Hyderabad. The move is part of the company’s broader strategy to expand its product pipeline and strengthen its presence in regulated global markets.

Key Highlights:

Investment Size: $1 million (approx. ₹8.7 crore)
Location: Hyderabad, Telangana
Focus Areas: API development, analytical research, and regulatory filings
Team Strength: 15–20 R&D scientists to lead innovation and product acceleration
Strategic Goal: Add six new Certificate of Suitability (CEP) filings in the next six months

The new facility will consolidate Sigachi’s API development and analytical capabilities under one roof, streamlining operations and boosting efficiency. It’s designed to support the company’s expansion into highvalue pharmaceutical ingredients and improve speedtomarket for new products.

CEO Amit Raj Sinha said the investment reflects Sigachi’s longterm commitment to innovation and global competitiveness. “We’re not just expanding infrastructure—we’re building a stronger, smarter pipeline,” he noted.

This development follows Sigachi’s 2023 acquisition of Trimax Bio Sciences in Karnataka and aligns with its goal of becoming a key player in regulated markets across Europe and North America.

With five manufacturing units already in operation and exports to over 65 countries, the new Hyderabad R&D centre marks a significant step in Sigachi’s evolution from a domestic leader to a global medtech contender.

Source: Economic Times, Angel One, Manufacturing Today India